Obicetrapib 67 items
The live agent: the phase 3 LDL-C programme, the CHMP opinion and the PREVAIL outcomes trial.
Trials, agents, guidance
- Agent Obicetrapib
- Trial Menarini European phase 3 (NCT07614958)
- Trial Obicetrapib CCTA imaging trial
- Trial TANDEM
- Trial BROOKLYN
- Trial PREVAIL
- Trial BROADWAY
Studies
- BROOKLYN: obicetrapib cuts LDL-C by 36.3% and Lp(a) by 45.9% in 354 patients with heterozygous familial hypercholesterolaemia (Nat Med 2026)
- BROADWAY substudy: obicetrapib cuts p-tau217 rise by a placebo-adjusted 20% in ApoE4/E4 carriers with cardiovascular disease (J Prev Alzheimers Dis 2026)
- Pooled analysis of 2,884 patients: obicetrapib cuts coronary events by 32% (HR 0.68) beyond 6 months, ahead of the PREVAIL readout (J Am Coll Cardiol 2025)
- TANDEM: obicetrapib plus ezetimibe fixed-dose combination cuts LDL-C by 48.6% versus placebo in 407 high-risk patients (Lancet 2025)
- BROADWAY: obicetrapib lowers LDL-C by 29.9% versus 2.7% with placebo in 2,530 high-risk patients (N Engl J Med 2025)
- In BROADWAY, obicetrapib slows p-tau217 progression, most in APOE4 carriers, positioning CETP inhibition against Alzheimer's disease (Am J Prev Cardiol 2026)
- TULIP: the original TA-8995 (obicetrapib) trial cuts LDL-C by up to 45.3% and raises HDL-C by up to 179% with no serious adverse events (Lancet 2015)
- Network meta-analysis of 6,025 patients: obicetrapib outperforms bempedoic acid for LDL-C lowering on top of statins by 15 percentage points (J Clin Lipidol 2026)
- Phase 2 trial in 102 Japanese patients: obicetrapib 10mg on background statin cuts LDL-C by 45.8% and raises HDL-C by 159% (J Atheroscler Thromb 2024)
- Phase 2 trial: obicetrapib plus ezetimibe on top of high-intensity statins cuts LDL-C by 63.4%, with 87% of patients reaching under 55 mg/dL (J Clin Lipidol 2023)
- Phase 2 trial in 120 patients: obicetrapib on top of high-intensity statins cuts LDL-C by up to 51% and raises HDL-C by up to 165% (Nat Med 2022)
- Obicetrapib lowers Lp(a) by 37% in a 2,356-patient pooled analysis, with similar absolute reduction across baseline strata (Eur Heart J 2026)
- CETP inhibitors reframed: from raising HDL to lowering atherogenic lipoproteins and improving glycaemic control, with obicetrapib the current lead (Circ Res 2026)
- CETP renaissance: a review maps obicetrapib reach beyond LDL-C into dementia, glycaemic control, sepsis and kidney function (Curr Atheroscler Rep 2026)
- From torcetrapib failure to obicetrapib promise: a full review of the mechanism and trial programme through PREVAIL (J Am Heart Assoc 2026)
- Network meta-analysis of 9,248 patients ranks obicetrapib plus ezetimibe plus statin best overall, obicetrapib plus statin safest among CETP-inhibitor combinations (J Cardiovasc Pharmacol 2026)
- Post hoc BROADWAY/BROOKLYN analysis: obicetrapib attenuates kidney function decline, tracking with achieved HDL-C (Am J Prev Cardiol 2026)
- Pooled phase 3 safety data on 2,880 patients show obicetrapib matches placebo for adverse events, with no blood pressure signal (Am J Prev Cardiol 2026)
- Network meta-analysis of 2,937 patients: obicetrapib outperforms anacetrapib on LDL-C, HDL-C and overall adverse events (Daru 2026)
- Obicetrapib review: an amphipathic CETP inhibitor cutting LDL-C 30-51%, apoB 20-33% and Lp(a) 30-57% across BROOKLYN, BROADWAY and TANDEM (Cardiol Rev 2025)
- GRADE-assessed meta-analysis of 3,399 patients: obicetrapib raises the odds of reaching an LDL-C target under 55 mg/dL more than sixfold (Diabetes Obes Metab 2026)
- Updated meta-analysis of 3,381 patients: obicetrapib cuts LDL-C by 37% and, unexpectedly, new-onset diabetes by 12% (Am J Prev Cardiol 2025)
- Network meta-analysis of 33 RCTs in 120,292 adults: atorvastatin plus obicetrapib ranks best for LDL-C, rosuvastatin plus obicetrapib best for HDL-C (Clin Cardiol 2025)
- CETP inhibition as a longevity pathway: apoB lowering, not HDL raising, is the mechanism, with signals in diabetes, dementia and kidney disease (Curr Opin Lipidol 2024)
- Beyond the heart: a review finds no excess macular degeneration risk across over 70,000 CETP-inhibitor trial patients, and surveys links to dementia, diabetes and sepsis (Pharmacol Res 2023)
- From raising HDL-C to lowering LDL-C: a review argues Mendelian randomisation and anacetrapib recast the whole CETP-inhibitor class (Cardiovasc Res 2022)
- CETP inhibition reduces major cardiovascular events through apoB lowering, a review argues, with obicetrapib cutting apoB by up to 30% (Int J Mol Sci 2022)
- TA-8995 (obicetrapib) raises ABCA1-specific cholesterol efflux capacity by 28% and preBeta-1 HDL by 36%, showing functional as well as HDL-C gains (J Clin Lipidol 2016)
- Meta-analysis of 3,512 patients: obicetrapib added to ezetimibe nearly doubles LDL-C lowering seen with obicetrapib alone, but adds nothing to statins (Cardiol Rev 2026)
- Meta-analysis of three RCTs in 3,286 patients confirms obicetrapib effects on LDL-C, apoB and HDL-C with no excess adverse events (Ann Med Surg 2026)
- Meta-analysis of 3,088 patients: obicetrapib cuts LDL-C by 32% and Lp(a) by 36% with no excess adverse events (Vasc Dis 2026)
- CETP inhibitors, state of the science: why torcetrapib, dalcetrapib, anacetrapib and evacetrapib failed and why obicetrapib is different (Curr Cardiol Rep 2026)
- Meta-analysis of 657 patients: obicetrapib combination therapy, especially with ezetimibe at 10mg, beats obicetrapib monotherapy for LDL-C lowering (Semergen 2026)
- Meta-analysis of nine RCTs in 3,516 patients confirms obicetrapib lowers LDL-C by 37% and Lp(a) by 41% with no excess adverse events (Cardiol Rev 2025)
- The two faces of CETP inhibitors: a review argues the therapeutic case has shifted from raising HDL-C to lowering apoB, with obicetrapib as proof (Curr Opin Lipidol 2025)
- REMBRANDT trial design: 300 ASCVD patients to test whether obicetrapib plus ezetimibe shrinks coronary plaque on CT angiography (Am Heart J 2025)
- Drug-drug interaction study finds no clinically meaningful effect of obicetrapib on atorvastatin or rosuvastatin exposure in healthy volunteers (Am J Cardiovasc Drugs 2025)
- Meta-analysis of nine RCTs in 3,706 patients: obicetrapib plus ezetimibe adds a further 17.8% LDL-C reduction over obicetrapib alone (J Clin Lipidol 2025)
- Unlike anacetrapib, obicetrapib clears completely from the body and does not accumulate in fat, monkey and human data show (Pharmacol Res Perspect 2024)
- Is obicetrapib a game changer? A review reframes CETP inhibition around apoB and LDL-C lowering rather than raising HDL-C (Expert Opin Pharmacother 2024)
- Obicetrapib, the rebirth of CETP inhibitors? A review of ROSE and ROSE2 phase 2 data ahead of four ongoing phase 3 trials (Curr Atheroscler Rep 2024)
- Population PK/PD model predicts obicetrapib ceiling effect: a maximum 51.1% LDL-C fall and 224% HDL-C rise (J Clin Pharmacol 2024)
- Rationale and design of BROADWAY and BROOKLYN: 2,886 participants randomised to test obicetrapib on top of maximally tolerated therapy (Am Heart J 2024)
- Reversing the tide of CETP inhibitor disappointments: a review of obicetrapib and its ROSE2 data ahead of pivotal phase 3 outcomes trials (Curr Atheroscler Rep 2024)
- HDL as a treatment target: a review says the obicetrapib outcomes trial will help decide whether to abandon the HDL hypothesis for good (Curr Atheroscler Rep 2023)
- First-in-human data: TA-8995 (obicetrapib) blocks 92-99% of CETP activity and is well tolerated across 1 to 150mg doses (Br J Clin Pharmacol 2014)
- Meta-analysis of five early RCTs in 288 patients: obicetrapib reduces LDL-C by 41% and raises HDL-C by 157% (J Clin Lipidol 2025)
- Lp(a) review names obicetrapib the only drug besides apheresis to meaningfully lower Lp(a), cutting it by 40% (Nutr Metab Cardiovasc Dis 2025)
- PK/PD trial in 48 healthy Chinese volunteers shows obicetrapib behaves like it does in White participants, supporting the global phase 3 programme (J Clin Pharmacol 2024)
- CETP pathophysiology and inhibition, an update: the drug class biology, trial status and adverse effects surveyed before obicetrapib phase 3 (Drug Discov Today 2021)
- CETP is over-expressed in non-small cell lung cancer and obicetrapib restores ferroptosis sensitivity in xenografts and organoids (Clin Transl Med 2026)
- In CETP mice, obicetrapib plus ezetimibe on top of atorvastatin regresses established atherosclerosis by 44% via LDL-receptor-driven VLDL clearance (J Lipid Res 2026)
- Machine learning and molecular dynamics show why obicetrapib binds the CETP hydrophobic tunnel more tightly than the failed torcetrapib (ChemMedChem 2025)
